The anabolic effects of GIP enhance both the postprandial glucose and lipid buffering capacity of white adipose tissue and prevent ectopic fat deposition in visceral organs (179, 180)
Not FDA-approved and associated with significant safety concerns including dangerous nausea, uncontrolled melanocytic changes (nevi/moles), hypertension, and priapism
For substantive edits, email us at [email protected] for review and approval
Side Effect Profiles and Tolerability Differences Both medications share common GLP-1 class side effects: nausea, vomiting, diarrhea, and constipation, typically mild to moderate and transient
Together they enhance tissue regeneration, synergistically combining to restore damaged structures [4, 6]